Global Jurisdictions Continue to Recognize Microbot Medical’s Innovative Technology; Receives Notice of Allowance for a U.S...
November 25 2019 - 7:00AM
Further demonstrating its commitment to expand and protect its
Intellectual Property (IP) portfolio, Microbot Medical Inc.
(Nasdaq: MBOT) was issued a Notice of Allowance for patent
application No. 15/936,878 by the U.S. Patent and Trademark Office
(USPTO). The allowed patent application covers the Company’s
TipCATTM technology platform.
“As we near the expected FDA pre-submission for
our first product, the Self Cleaning Shunt (SCSTM), we have also
experienced an acceleration in the expansion of our patent estate –
with this latest allowance being the 5th to date in 2019 and across
several global jurisdictions, including North America and Europe,”
said Harel Gadot, Chief Executive Officer, President, and Chairman.
“As we identify and pursue future product offerings in the
fast-growing, minimally invasive surgical robotics market,
protecting our assets and creating formidable barriers to entry
through a proactive and effective global patent portfolio strategy
is fundamental to building value for our shareholders and other
stakeholders.”
The allowed patent application is a Continuation
of Patent No. 9,937,326, issued on April 10, 2018, which is a
Continuation of Patent No. 9,061,118, issued on June 23, 2015. It
covers a self-propelled device for locomotion through a lumen, the
device comprising a set of serially arranged inflatable chambers
configured for sequential inflation from a single fluid source,
wherein the outer skin of at least one of the chambers has at least
one longitudinal section of greater rigidity than other sections of
the outer skin, such that when that chamber inflates, the set of
chambers transitions to a bent state.
Globally, the Company now has 35 patents
issued/allowed and 16 patent applications pending worldwide.
About Microbot Medical,
Inc.
Microbot™ specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
technological platforms, ViRobTM, TipCATTM and CardioSertTM, are
comprised of three highly advanced technologies, from which the
Company is currently developing its first product candidate: The
Self-Cleaning Shunt, or SCSTM, for the treatment of hydrocephalus
and Normal Pressure Hydrocephalus, or NPH. The Company also is
focused on the development of a Multi Generation Pipeline Portfolio
(MGPP) utilizing all technologies. Further information about
Microbot Medical is available at
http://www.microbotmedical.com.
The ViRobTM technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to navigate and
crawl in different spaces within the human body, including blood
vessels, the digestive tract and the respiratory system. Its unique
structure gives it the ability to move in tight spaces and curved
passages as well as the ability to remain within the human body for
prolonged time. To learn more about ViRobTM please visit
http://www.microbotmedical.com/technology/virob/.
TipCATTM is a transformational self-propelled,
flexible, and semi-disposable locomotive device providing see &
treat capabilities within tubular lumens in the human body such as
the colon, blood vessels, and the urinary tract. Its
locomotion mechanism is perfectly suitable to navigate and crawl
through natural & artificial tubular lumens, applying the
minimal necessary pressure to achieve the adequate friction
required for gentle, fast, and safe advancement within the human
body. To learn more about TipCATTM, visit
http://www.microbotmedical.com/technology/tipcat/.
CardioSertTM technology contemplates a unique
combination of a guidewire and microcatheter, technologies that are
broadly used for endoluminal surgery. The CardioSertTM technology
features unique steering and stiffness control capabilities, and it
was originally developed to support interventional cardiologists in
crossing the most complex lesions called chronic total occlusion
(CTO) during percutaneous coronary intervention (PCI) procedures
and has the potential to be used in other spaces and applications,
such as peripheral intervention, neurosurgery and urology.
CardioSertTM was part of a technological incubator supported by the
Israel Innovation Authorities (formerly known as the Office of the
Chief Scientist, or OCS), and its device has successfully completed
pre-clinical testing.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, the
outcome of its studies to evaluate the SCS and other existing and
future technologies, uncertainty in the results of pre-clinical and
clinical trials or regulatory pathways and regulatory approvals,
need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially
from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many
uncertainties that affect the businesses of Microbot Medical Inc.
particularly those mentioned in the cautionary statements found in
Microbot Medical Inc.’s filings with the Securities and Exchange
Commission. Microbot Medical disclaims any intent or obligation to
update these forward-looking statements.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024